Melanotan II Research Guide — Melanocortin Receptor Agonism and Pigmentation Biology

Research Use Only. All OL Research products are supplied strictly for in-vitro and laboratory research purposes. They are not medicines, food supplements, or cosmetic ingredients. Not for human or veterinary use. This article is written for educational and scientific reference only.

What is Melanotan II?

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH). Its sequence is Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, incorporating a D-phenylalanine substitution and a lactam bridge cyclisation that confers significantly greater potency and metabolic stability compared to the linear native peptide. Developed at the University of Arizona in the late 1980s and 1990s, Melanotan II became an important research tool for dissecting the melanocortin receptor system and its diverse physiological roles.

Melanotan II has a molecular weight of 1024.2 Da and is the parent compound from which PT-141 (bremelanotide) — a des-amidated metabolite — was subsequently derived. Understanding MT-II’s receptor pharmacology is therefore foundational to understanding PT-141.

The Melanocortin Receptor System

The melanocortin system comprises five G protein-coupled receptors (MC1R–MC5R), the endogenous agonists α-MSH, β-MSH, and γ-MSH (all POMC-derived), and the endogenous antagonists agouti signalling protein (ASIP) and agouti-related protein (AgRP). Each receptor has a distinct tissue distribution and physiological function:

MC1R — primarily expressed on melanocytes; regulates eumelanin (brown/black) vs phaeomelanin (red/yellow) synthesis
MC2R — expressed in adrenal cortex; mediates ACTH-stimulated cortisol production
MC3R — expressed in hypothalamus, limbic system, gut; involved in energy homeostasis and reproductive function
MC4R — widely expressed in CNS; critical regulator of appetite, energy expenditure, and sexual function
MC5R — expressed in exocrine glands; roles in thermoregulation and exocrine secretion

Melanotan II is a non-selective agonist, binding with nanomolar affinity to MC1R, MC3R, MC4R, and MC5R. It does not significantly bind MC2R. This broad receptor profile makes it a useful research tool for studying multiple melanocortin axes simultaneously, though it also means observed effects in experimental systems must be interpreted in the context of potential multi-receptor engagement.

Skin Pigmentation Research

MC1R activation by MT-II on melanocytes triggers the cAMP-PKA signalling cascade, leading to upregulation of MITF (microphthalmia-associated transcription factor) and downstream expression of tyrosinase — the rate-limiting enzyme in melanin synthesis. The resulting shift in melanin production towards eumelanin (the photoprotective dark pigment) has been studied in cell culture models using B16 melanoma cells, primary human melanocytes, and reconstructed skin models.

Research parameters in melanocyte biology experiments typically include melanin content quantification (by NaOH solubilisation and spectrophotometry at 405 nm), tyrosinase activity assays, and MITF expression by RT-PCR and western blotting. Researchers should be aware that B16 cells have constitutively elevated MITF and may respond differently from primary melanocytes; primary cells from donors with different MC1R polymorphisms (which alter receptor function) can introduce significant inter-sample variability.

Central Melanocortin Research: Appetite and Energy Metabolism

MC4R expression in the hypothalamic paraventricular nucleus (PVN) and other feeding-related nuclei positions the melanocortin system as a key regulator of energy balance. MC4R knockout mice are obese, and MC4R is the most common single-gene cause of monogenic human obesity. Melanotan II’s high MC4R affinity has made it a standard pharmacological tool in appetite and metabolism research, used to acutely suppress food intake and to investigate hypothalamic melanocortin circuitry in rodent models.

Researchers studying the melanocortin-energy balance axis typically use intracerebroventricular (ICV) administration in rodent models to target central receptors directly, complemented by measurements of food intake, body weight, and metabolic parameters. Peripheral administration engages both central and peripheral MCRs.

Melanotan II vs PT-141: Structural and Pharmacological Comparison

PT-141 (bremelanotide) is the des-amidated form of Melanotan II, differing only in the C-terminal modification. Despite this minor structural difference, PT-141 has a distinct pharmacological profile: it retains potent MC3R and MC4R agonism but has lower MC1R affinity, reducing its pigmentation-related effects relative to MT-II. This makes PT-141 more selective for central melanocortin research applications.

See our dedicated PT-141 vs Melanotan II comparison guide for a detailed structural and pharmacological analysis, and our PT-141 research guide for coverage of central MC3R/MC4R research applications. For the melanocortin anti-inflammatory axis relevant to KPV research, see our KPV peptide research guide.

Laboratory Considerations

Melanotan II is supplied as a lyophilised powder and should be reconstituted in sterile water or bacteriostatic water. It is light-sensitive and solutions should be stored protected from light at 4°C with prompt use after reconstitution. For in-vitro melanocyte work, MT-II is typically used at concentrations of 1–100 nM; for receptor binding studies, radiolabelled analogues or competitive binding assays with fluorescent probes are used to establish binding affinities and compare receptor selectivity profiles.